Copyright
©The Author(s) 2016.
World J Nephrol. Jan 6, 2016; 5(1): 6-19
Published online Jan 6, 2016. doi: 10.5527/wjn.v5.i1.6
Published online Jan 6, 2016. doi: 10.5527/wjn.v5.i1.6
Level 1 | Control blood pressure (sitting systolic BP in the 120 s) |
ACE inhibitor or ARB therapy with up-titration of dosage or combination ACE inhibitor and ARB therapy | |
Level 2 | Control protein intake |
Restrict NaCl intake/institute diuretic therapy | |
Control each component of the metabolic syndrome | |
Aldosterone antagonist therapy | |
Beta-blocker therapy | |
Smoking cessation | |
Other measures | Allopurinol therapy |
Empiric NaHCO3 therapy, independent of whether metabolic acidosis is present or not | |
Avoid NSAIDs altogether, or no more than once or twice weekly at most | |
Avoid prolonged severe hypokalemia | |
Avoid phosphate cathartics | |
Ergocalciferol therapy to correct vitamin D deficiency | |
Control hyperphosphatemia and hyperparathyroidism |
- Citation: Salvadori M, Rosso G. Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects. World J Nephrol 2016; 5(1): 6-19
- URL: https://www.wjgnet.com/2220-6124/full/v5/i1/6.htm
- DOI: https://dx.doi.org/10.5527/wjn.v5.i1.6